NEWRON PHARMACEUT. EO-20 (NP5) — Net Asset Quality Index
NEWRON PHARMACEUT. EO-20 (NP5) has a Net Asset Quality Index of -27.8% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €40.03 Million minus total liabilities of €51.15 Million yields net assets of €-11.13 Million. A higher index indicates a stronger, lower-leverage balance sheet. See operational self-sufficiency of NEWRON PHARMACEUT. EO-20 to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
NEWRON PHARMACEUT. EO-20 Net Asset Quality Index Over Time (2005–2025)
This chart shows how NEWRON PHARMACEUT. EO-20's Net Asset Quality Index has evolved across 21 annual periods from 2005 to 2025. As of December 2025, the index stands at -27.8%, representing net assets of €-11.13 Million against total assets of €40.03 Million EUR. Explore NP5 operating cash flow to assess how effectively this company generates cash.
Annual Net Asset Quality Index for NEWRON PHARMACEUT. EO-20 (2005–2025)
The table below presents the year-by-year Net Asset Quality Index for NEWRON PHARMACEUT. EO-20 from 2005 to 2025, covering 21 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see NEWRON PHARMACEUT. EO-20 (NP5) total market value.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -27.8% | €-11.13 Million | €40.03 Million | €51.15 Million | ▼ -30.1 pp |
| 2024 | 2.3% | €1.46 Million | €63.91 Million | €62.45 Million | ▲ +117.9 pp |
| 2023 | -115.6% | €-29.91 Million | €25.87 Million | €55.77 Million | ▼ -77.9 pp |
| 2022 | -37.7% | €-14.03 Million | €37.20 Million | €51.23 Million | ▼ -43.9 pp |
| 2021 | 6.2% | €3.11 Million | €50.49 Million | €47.38 Million | ▼ -27.5 pp |
| 2020 | 33.7% | €17.25 Million | €51.20 Million | €33.95 Million | ▼ -27.4 pp |
| 2019 | 61.0% | €36.80 Million | €60.29 Million | €23.49 Million | ▼ -30.4 pp |
| 2018 | 91.4% | €54.84 Million | €60.00 Million | €5.16 Million | ▼ -1.3 pp |
| 2017 | 92.7% | €67.72 Million | €73.02 Million | €5.30 Million | ▲ +4.8 pp |
| 2016 | 87.9% | €49.75 Million | €56.59 Million | €6.84 Million | ▲ +4.3 pp |
| 2015 | 83.6% | €37.11 Million | €44.38 Million | €7.27 Million | ▲ +4.7 pp |
| 2014 | 78.9% | €29.26 Million | €37.07 Million | €7.81 Million | ▲ +12.2 pp |
| 2013 | 66.7% | €21.09 Million | €31.62 Million | €10.53 Million | ▲ +4.9 pp |
| 2012 | 61.8% | €27.61 Million | €44.65 Million | €17.04 Million | ▲ +13.3 pp |
| 2011 | 48.5% | €6.58 Million | €13.57 Million | €6.98 Million | ▼ -15.2 pp |
| 2010 | 63.7% | €12.19 Million | €19.13 Million | €6.94 Million | ▼ -6.5 pp |
| 2009 | 70.3% | €29.28 Million | €41.68 Million | €12.39 Million | ▼ -5.4 pp |
| 2008 | 75.7% | €45.81 Million | €60.54 Million | €14.73 Million | ▼ -5.9 pp |
| 2007 | 81.6% | €57.40 Million | €70.37 Million | €12.97 Million | ▲ +2.8 pp |
| 2006 | 78.8% | €67.86 Million | €86.16 Million | €18.30 Million | ▲ +6.3 pp |
| 2005 | 72.4% | €17.02 Million | €23.50 Million | €6.48 Million | — |